China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced a significant licensing agreement with Australia-based AFT Pharmaceuticals Ltd (NZE: AFT, ASX: AFP). Through this agreement, Hainan Haiyao has obtained exclusive distribution rights to AFT Pharmaceuticals’ range of products in China, including Lipo-Sachets liposomal Vitamin C, Lipo-Sachets liposomal Vitamin D3, Ferro LipoSachets iron supplement, and Kiwisooche chewable tablets.
Ten-Year Agreement Builds on Previous Partnership
The ten-year deal, with financial details undisclosed, expands upon the existing partnership between Hainan Haiyao and AFT Pharmaceuticals, which was initially established in relation to the distribution of Crystaderm cream. This new agreement signifies a deepening collaboration between the two companies, aiming to bring a wider range of AFT’s innovative nutritional products to the Chinese market.
Expanding Access to Liposomal Nutrients and Supplements
The products covered under the agreement include advanced liposomal formulations of essential vitamins and supplements. Lipo-Sachets technology enhances the absorption and bioavailability of nutrients, providing consumers with more effective health solutions. The addition of these products to Hainan Haiyao’s portfolio is expected to cater to the growing demand for high-quality nutritional products in China.-Fineline Info & Tech
